NEW YORK, NY -- (MARKET WIRE) -- September 28, 2006 -- China Aoxing Pharmaceutical Corp. (OTCBB: CAXG) announced that its subsidiary, Hebei Aoxing Pharmaceutical Group (“Aoxing”), received a research and development grant of RMB 500,000 ($62,500 USD) for its ongoing Tilidine capsule research project. This grant was authorized by the order of Hebei Legislation Charter 86, and was jointly issued by the Treasury Department of Hebei Province and the Hebei Reform and Development Committee.
